ClinicalTrials.gg
CompletedNCT06181760Updated Jan 27, 2025Results posted

A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers

A Phase 1 interventional study of Fenretinide and Placebo in Safety and Tolerability, sponsored by Island Pharmaceuticals. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Island Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial was to learn about a single dose of fenretinide in healthy volunteers, in both a fasted and fed state. The main questions to answer were:

  • How well is a single dose of fenretinide tolerated? AND
  • How is a single dose of fenretinide metabolized in healthy volunteers?

Participants will be asked to:

  • Remain confined in a clinical research unit for 5 days after dosing.
  • Provide blood samples for intense PK sampling and safety labs.
  • Fast for 10 hours prior to administration of study drug (fasted cohorts).
  • Consume a high fat meal prior to administration of study drug (fed cohort).
  • Return to the clinic for a single follow-up visit for safety assessments.

The study will compare active fenretinide to placebo to see if fenretinide is more or less tolerable than placebo.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled single ascending dose study. There are 3 planned dose-level cohorts (Cohorts 1-3). Each dose-level cohort will consist of 8 subjects (6 active + 2 placebo), who will be treated under fasted conditions. The subjects in the highest tolerated dose-level cohort (determined by the Safety Review Committee) will also be administered ISLA101 or placebo under fed conditions, in a cross-over manner (Cohort 4).

Proposed doses are 300, 600, and 900 mg/m\^2 (equivalent to 8.1, 16.2, and 24.3 mg/kg). Each subject will be allocated to 1 dose level only.

The study will include a 5-day stay in the clinical research unit followed by a final safety follow-up visit at Day 8, where subjects will be under fasted conditions when they are dosed on Study Day 1.

For cohort 4, the study will again include a 5-day stay in the clinical research unit followed by a final safety follow-up visit at Day 17, where subjects will be under fed conditions when they are dosed on Study Day 10.

02

Conditions studied

  • Safety and Tolerability
03

In context

Lead sponsor

Island Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female volunteers not of , who are 18 years to 65 years of age (inclusive) at the time of signing the form (ICF).
  2. Females not of childbearing potential, as defined in the following criteria:

    1. History of hysterectomy.
    2. .

    i. Natural post-menopausal females with at least 12 months from natural spontaneous amenorrhea and a serum follicle-stimulating hormone (FSH) concentration ≥ 40 IU/L.

    ii. Post-surgical females must have undergone bilateral oophorectomy at least 6 weeks prior to study.

  3. Male subjects with female partners of childbearing potential must agree to practice abstinence or use a combination of 2 of the following acceptable methods during the study and for at least 90 days after dosing:

    1. Partners have an intrauterine device (IUD) without hormones in place for at least 3 months.
    2. Barrier method (condom or diaphragm) for at least 14 days prior to screening and 90 days after dosing with study drug.
    3. Partners using stable hormonal contraceptive for at least 3 months prior to screening and for 90 days after dosing with study drug.
    4. History of vasectomy at least 3 months prior to signing the ICF.
  4. Must be able to understand and provide signed informed consent for study participation.
  5. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
  6. (BMI) 18.0 to 32.0 kg/m2 (inclusive), and a body weight ≥ 50 kg.
  7. Normal renal function, defined as estimated (eGFR) ≥ 70 mL/min/1.73 m2 at screening and Day -1.
  8. Clinical laboratory values should be within the laboratory's stated normal range. If not within this range, they must be without clinical significance, as determined by the Investigator.
  9. No history of medical disorders, as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected pregnancy (confirmed via a positive serum human chorionic gonadotropin [hCG] pregnancy test at screening), planned pregnancy during the study period, nursing, or lactation.
  2. Women of or men who intend to father a child or donate sperm during the study period and for 3 months after study drug administration.
  3. Known allergy to fenretinide or any of the components of ISLA101.
  4. Evidence or history of medical conditions, such as hematological, renal, endocrine (e.g., polycystic ovarian syndrome or other anovulatory states), immunologic, pulmonary, metabolic, gastrointestinal (e.g., Crohn's disease, acute or chronic pancreatitis, and others) and surgery (except for simple appendectomy or repair of a hernia), which all can influence the absorption of study drug; cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), or any other illness that the Investigator considers exclusionary or that could interfere with the interpretation of the study results.
  5. History of severe infectious disease or recurrent infections.
  6. (AST), alanine aminotransferase (ALT), or total above the 1.5 x (ULN) at screening and Day -1.
  7. Clinically significant (ECG) abnormalities or vital sign abnormalities at screening and Day -1, long syndrome, or a history of cardiac disease.
  8. Abnormal diet that may affect absorption, distribution, metabolism, or excretion of drugs, for example, lacking standard nutrients (e.g, cleansing diet 2 weeks before or during the study).
  9. Positive result for , , or (HIV) at screening.
  10. History of positive test for tuberculosis (TB) at screening.
  11. A subject who has donated 1 unit of blood of over 500 mL within 56 days prior to the study drug administration, or donated plasma within 14 days prior to study drug administration.
  12. Use of systemic antibiotics within 30 days prior to dosing.
  13. Any use of drugs that inhibit or induce CYP enzymes within 30 days prior to administration of study drug and for the duration of study participation.
  14. Use of any tobacco products, e-cigarettes, and/or nicotine replacement products in the 3 months preceding screening.
  15. Any food allergy, intolerance, or restriction that, in the opinion of the Investigator, could contraindicate the subject's participation in this study.
  16. Recent history of (within the past 12 months), or strong potential for, alcohol or substance abuse. Alcohol abuse will be defined as > 14 drinks per week (1 drink = 10g of ethanol).
  17. History of drug or alcohol abuse within 5 years before screening or positive result of UDS (e.g, amphetamines, benzodiazepines, cannabinoids, cocaine, hallucinogens, opiates) or alcohol breath test at screening.
  18. Exposure to any agent or used an invasive investigational medical device within 30 days or within a period less than 5 drug half-lives prior to study entry (whichever is longer).
  19. Study site employees, Sponsor's employees, or immediate family members of a study site or Sponsor employee.
  20. Previously enrolled in this study.
  21. Vaccination 14 days from screening or plans to get a vaccine within 30 days after dosing.
  22. Acute infection (such as influenza) or relevant lesion at the time of Screening or Day -1. Subjects can be rescreened once they have recovered.
  23. Criteria at the discretion of the Investigator:

    1. Chronic medical condition that impacts subject safety.
    2. Clinically significant abnormal physical examination or vital signs at screening.
    3. Condition believed to interfere with the subject's ability to provide or comply with study instructions, or that might confound the interpretation of the study results or put the subject at undue risk.
    4. History or evidence of a clinically significant disorder, condition, or disease that that is believed to significantly impair pain perception (e.g., history of stroke, history of neuropathy), would pose a risk to subject safety or interfere with evaluation, procedures, or study completion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Fenretinide 300 mg/m^2

    Single oral dose of fenretinide, 300 mg/m\^2 under fasted conditions (Phase 1)

    Drug: Fenretinide

  • Active comparator
    Fenretinide 600 mg/m^2

    Single oral dose of fenretinide, 600 mg/m\^2 under fasted conditions (Phase 1) Once all groups finish Phase 1, return to complete Phase 2 with a single oral dose of fenretinide, 600 mg/m\^2 under fed conditions per recommendation from the independent Safety Review Committee.

    Drug: Fenretinide

  • Active comparator
    Fenretinide 900 mg/m^2

    Single oral dose of fenretinide, 900 mg/m\^2 under fasted conditions (Phase 1)

    Drug: Fenretinide

  • Placebo comparator
    Placebo

    Single oral dose of placebo capsules under fasted conditions (Phase 1) Once all groups finish Phase 1, return to complete Phase 2 with a single oral dose of placebo capsules under fed conditions per recommendation from the independent Safety Review Committee.

    Drug: Placebo

Interventions

  • Ascending single doses of oral fenretinide

  • DrugPlacebo

    Single oral dose of matching placebo capsules

06

What researchers measure

Primary outcomes

  1. Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions

    Time frame: First Intervention (Day 1 to Day 8)

  2. Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions

    25 total subjects were enrolled in the study.

    Time frame: First Intervention (Day 1 to Day 8)

  3. Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions

    Subjects in the 600 mg/m\^2 came back to complete the fed cohort, as this was the only group to return based on the recommendations by the Safety Review Committee. Only 4 out of the 6 subjects returned for this cohort (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

    Time frame: Second Intervention (Day 9 to Day 17)

  4. Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions

    25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

    Time frame: Second Intervention (Day 9 to 17)

Secondary outcomes

  1. Assess the CMax - Observed Maximum Plasma Concentration Following a Single Oral Dose of Fenretinide

    Secondary objective

    Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)

  2. Assess the TMax - Time to Reach Maximum Concentration Curve Following a Single Oral Dose of Fenretinide in the Fasted and Fed State

    25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

    Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)

  3. Assess the AUC-∞ Area Under the Concentration Curve From Zero to Infinite Time Following a Single Oral Dose of Fenretinide in the Fasted and Fed State

    25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

    Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)

  4. Assess the AUC(Last) - Area Under the Curve up to the Last Quantifiable Timepoint After a Single Oral Dose of Fenretinide in the Fasted and Fed State

    25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

    Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)

  5. Assess the Half Life of a Single Oral Dose of Fenretinide in the Fasted and Fed State

    25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

    Time frame: First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)

07

Results

Posted Jan 27, 2025

Participant flow

First Intervention (Fasted)
Participant flow — First Intervention (Fasted)
MilestoneFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2Placebo
Started6667
Completed6666
Not completed0001
Withdrew: Withdrawal by subject0001
Second Intervention (Fed)
Participant flow — Second Intervention (Fed)
MilestoneFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2Placebo
Started0301
Completed0301
Not completed0000

Outcome measures

PrimaryNumber and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions
Time frame:
First Intervention (Day 1 to Day 8)
Reported as:
Count of participants · Participants
Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions
ParticipantsFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2Placebo
Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions1232
PrimaryNumber and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions

25 total subjects were enrolled in the study.

Time frame:
First Intervention (Day 1 to Day 8)
Reported as:
Count of participants · Participants
Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions
ParticipantsFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2Placebo
Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions0000
SecondaryAssess the CMax - Observed Maximum Plasma Concentration Following a Single Oral Dose of Fenretinide

Secondary objective

Time frame:
First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Reported as:
Mean · ng/mL
Assess the CMax - Observed Maximum Plasma Concentration Following a Single Oral Dose of Fenretinide
ng/mLFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboFenretinide 600 mg/m^2 (Fed)Placebo (Fed)
Assess the CMax - Observed Maximum Plasma Concentration Following a Single Oral Dose of Fenretinide195.8 ± 92.35524.8 ± 74.2624.2 ± 142.2—1455 ± 521.6—
SecondaryAssess the TMax - Time to Reach Maximum Concentration Curve Following a Single Oral Dose of Fenretinide in the Fasted and Fed State

25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Time frame:
First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Reported as:
Mean · hours
Assess the TMax - Time to Reach Maximum Concentration Curve Following a Single Oral Dose of Fenretinide in the Fasted and Fed State
hoursFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboFenretinide 600 mg/m^2 (Fed)Placebo (Fed)
Assess the TMax - Time to Reach Maximum Concentration Curve Following a Single Oral Dose of Fenretinide in the Fasted and Fed State5.895 (2.97 to 6.0)5.15 (5.07 to 6.02)5.015 (4.88 to 6.0)—5.98 (5.98 to 9.97)—
SecondaryAssess the AUC-∞ Area Under the Concentration Curve From Zero to Infinite Time Following a Single Oral Dose of Fenretinide in the Fasted and Fed State

25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Time frame:
First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Reported as:
Mean · h*ng/mL
Assess the AUC-∞ Area Under the Concentration Curve From Zero to Infinite Time Following a Single Oral Dose of Fenretinide in the Fasted and Fed State
h*ng/mLFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboFenretinide 600 mg/m^2 (Fed)Placebo (Fed)
Assess the AUC-∞ Area Under the Concentration Curve From Zero to Infinite Time Following a Single Oral Dose of Fenretinide in the Fasted and Fed State3479 ± 19478209 ± 836.99621 ± 2145—25800 ± 8726—
SecondaryAssess the AUC(Last) - Area Under the Curve up to the Last Quantifiable Timepoint After a Single Oral Dose of Fenretinide in the Fasted and Fed State

25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Time frame:
First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Reported as:
Mean · h*ng/mL
Assess the AUC(Last) - Area Under the Curve up to the Last Quantifiable Timepoint After a Single Oral Dose of Fenretinide in the Fasted and Fed State
h*ng/mLFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboFenretinide 600 mg/m^2 (Fed)Placebo (Fed)
Assess the AUC(Last) - Area Under the Curve up to the Last Quantifiable Timepoint After a Single Oral Dose of Fenretinide in the Fasted and Fed State3212 ± 17957894 ± 844.69089 ± 2039—24460 ± 8395—
SecondaryAssess the Half Life of a Single Oral Dose of Fenretinide in the Fasted and Fed State

25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Time frame:
First Intervention (Day 1 to Day 8), washout period, Second Intervention (Day 9-17)
Reported as:
Mean · hours
Assess the Half Life of a Single Oral Dose of Fenretinide in the Fasted and Fed State
hoursFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboFenretinide 600 mg/m^2 (Fed)Placebo (Fed)
Assess the Half Life of a Single Oral Dose of Fenretinide in the Fasted and Fed State22.41 (9.788 to 35.73)28.21 (22.21 to 42.64)26.67 (21.23 to 29.47)—27.77 (26.41 to 29.23)—
PrimaryNumber and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions

Subjects in the 600 mg/m\^2 came back to complete the fed cohort, as this was the only group to return based on the recommendations by the Safety Review Committee. Only 4 out of the 6 subjects returned for this cohort (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Time frame:
Second Intervention (Day 9 to Day 17)
Reported as:
Count of participants · Participants
Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions
ParticipantsFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2Placebo
Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions0000
PrimaryNumber and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions

25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Time frame:
Second Intervention (Day 9 to 17)
Reported as:
Count of participants · Participants
Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions
ParticipantsFenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2Placebo
Number and % of Subjects Experiencing Serious Adverse Events Following a Single Oral Dose of Fenretinide Under Fed Conditions0000

Adverse events

Collected over Subjects were monitored throughout the study for adverse reactions to the study drug and/or procedures from the time of informed consent through end of study (either through Day 8 for the fasted cohorts or through Day 17 for the fed cohort).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fenretinide 300 mg/m^2 (First Intervention)0/6 (0%)0/6 (0%)1/6 (16.7%)
Fenretinide 600 mg/m^2 (First Intervention)0/6 (0%)0/6 (0%)2/6 (33.3%)
Fenretinide 900 mg/m^2 (First Intervention)0/6 (0%)0/6 (0%)3/6 (50%)
Placebo (First Intervention)0/7 (0%)0/7 (0%)2/7 (28.6%)
Fenretinide 600 mg/m^2 (Second Intervention)0/3 (0%)0/3 (0%)0/3 (0%)
Placebo (Second Intervention)0/1 (0%)0/1 (0%)0/1 (0%)
Most frequent other events
Most frequent other events
EventFenretinide 300 mg/m^2 (First Intervention)Fenretinide 600 mg/m^2 (First Intervention)Fenretinide 900 mg/m^2 (First Intervention)Placebo (First Intervention)Fenretinide 600 mg/m^2 (Second Intervention)Placebo (Second Intervention)
diarrheaGastrointestinal disorders0/61/60/61/70/30/1
neutropeniaBlood and lymphatic system disorders0/61/60/60/70/30/1
PhotophobiaEye disorders0/61/60/60/70/30/1
vascular access site thrombosisGeneral disorders0/60/61/61/70/30/1
musculoskeletal painMusculoskeletal and connective tissue disorders1/60/60/60/70/30/1
lethargyNervous system disorders0/60/61/60/70/30/1
dry skinSkin and subcutaneous tissue disorders0/61/60/60/70/30/1
Haematoma muscleInjury, poisoning and procedural complications0/60/61/60/70/30/1

Baseline characteristics

25 total subjects were enrolled in the study. After all fasted cohorts completed (i.e., 300 mg/m\^2, 600 mg/m\^2, 900 mg/m\^2 as well as placebo) data was reviewed by the independent Safety Review Committee. The recommendation was to bring back the 600 mg/m\^2 group to complete the fed cohort and only 4 out of the 6 subjects were available (i.e., 3 subjects on ISLA101 and 1 subject on placebo).

Age, Continuous
Age, Continuous(years)Fenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboTotal
Mean32.57 ± 10.44340.23 ± 9.43834.33 ± 13.04930.66 ± 10.58834.3 ± 10.872
Sex: Female, Male
Sex: Female, Male(Participants)Fenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboTotal
Female11002
Male556723
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboTotal
American Indian or Alaska Native10001
Asian13329
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White413412
More than one race00000
Unknown or Not Reported02013
Region of Enrollment
Region of Enrollment(participants)Fenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboTotal
Australia666725
Body Mass Index
Body Mass Index(kg/m^2)Fenretinide 300 mg/m^2Fenretinide 600 mg/m^2Fenretinide 900 mg/m^2PlaceboTotal
Mean24.9 ± 4.3526.3 ± 4.4022.78 ± 2.7924.31 ± 3.1224.56 ± 3.69
08

Study locations

1 site
  • Island Site 01
    Randwick, New South Wales 2031, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2024, 2 months.

Results were first posted in Jan 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Dec 26, 2023
StartActual
Nov 22, 2023
Primary completionActual
Feb 13, 2024
CompletionActual
Feb 13, 2024
Results first posted
Jan 27, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06181760
Lead sponsor
Island Pharmaceuticals
Collaborators
Beyond Drug Development
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Nov 22, 2023
Primary completion
Feb 13, 2024
Completion
Feb 13, 2024
Results posted
Jan 27, 2025
Last update
Jan 27, 2025

Study contacts

Christopher Argent, MD
principal investigator · Scientia Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenretinide

Other studies from this sponsor

Island Pharmaceuticals

Start the discussion